Interestingly, for rectal cancer, SEPT9 methylation levels were significantly higher in stage IV than in stages I, II or III (P = 0.001), whereas both MGMT and SEPT9 methylation levels were significantly lower in patients that underwent neoadjuvant treatment (P = 0.012 and P = 0.002, respectively). This evidence concerns the gene SEPTIN9 and rectal cancer.